Endpoints News met with Vida’s Co-founder and Managing Director, Arjun Goyal, M.D., to discuss #ThirdArcBio’s oversubscribed Series A launch and what’s to come for this accomplished team and their potential best-in-class therapies. Link to article: https://bit.ly/3SlcIdJ
Third Arc Bio originally sought $100 million for its Series A, but with a star-studded executive team that has brought more than 15 new medicines to market, the biotech ended up reeling in $165 million. Founded by Johnson & Johnson veteran Sanjaya Singh and led by former J&J global oncology leader Peter Lebowitz, the Philadelphia-area startup will test its multispecific antibodies in solid tumors and I&I conditions starting next year. Its Series A includes many crossover and public investors, giving the nascent company multiple options before its capital runs dry in roughly three years. “At J&J, I saw all the platforms. We had them all. I specifically wanted to work on [multispecific antibodies] because this is the area where there is the largest opportunity to meet unmet need,” Lebowitz said in an interview with Endpoints News. “There’s a lot of interest in ADCs now, and ADCs are very important. But this is the area that is right in the right spot of the breaking point where it goes over the edge and actually is transformational for solid tumors.” #biotech #venturecapital #biotechvc #thirdarc #biologics #multispecificantibodies #solidtumors #autoimmune #immunology #drugdevelopment